Vaxart Non Current Assets Total from 2010 to 2024
| VXRT Stock | USD 0.78 0.02 2.50% |
Non Current Assets Total | First Reported 1985-12-31 | Previous Quarter 46.3 M | Current Value 44.4 M | Quarterly Volatility 61.8 M |
Check Vaxart financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxart's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.4 M, Interest Expense of 1.4 M or Total Revenue of 7 M, as well as many indicators such as Price To Sales Ratio of 10.68, Dividend Yield of 0.0 or PTB Ratio of 2.42. Vaxart financial statements analysis is a perfect complement when working with Vaxart Valuation or Volatility modules.
Vaxart | Non Current Assets Total |
Latest Vaxart's Non Current Assets Total Growth Pattern
Below is the plot of the Non Current Assets Total of Vaxart Inc over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. Vaxart's Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxart's overall financial position and show how it may be relating to other accounts over time.
| Non Current Assets Total | 10 Years Trend |
|
Non Current Assets Total |
| Timeline |
Vaxart Non Current Assets Total Regression Statistics
| Arithmetic Mean | 19,483,209 | |
| Geometric Mean | 6,620,688 | |
| Coefficient Of Variation | 101.04 | |
| Mean Deviation | 16,110,784 | |
| Median | 12,900,000 | |
| Standard Deviation | 19,686,261 | |
| Sample Variance | 387.5T | |
| Range | 54.3M | |
| R-Value | 0.85 | |
| Mean Square Error | 114.2T | |
| R-Squared | 0.73 | |
| Significance | 0.000055 | |
| Slope | 3,751,750 | |
| Total Sum of Squares | 5425.7T |
Vaxart Non Current Assets Total History
About Vaxart Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Vaxart income statement, its balance sheet, and the statement of cash flows. Vaxart investors use historical funamental indicators, such as Vaxart's Non Current Assets Total, to determine how well the company is positioned to perform in the future. Although Vaxart investors may use each financial statement separately, they are all related. The changes in Vaxart's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Vaxart's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Vaxart Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Vaxart. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Assets Total | 46.3 M | 40.4 M |
Pair Trading with Vaxart
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vaxart position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vaxart will appreciate offsetting losses from the drop in the long position's value.Moving together with Vaxart Stock
| 0.68 | EGRX | Eagle Pharmaceuticals Upward Rally | PairCorr |
| 0.77 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.82 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
Moving against Vaxart Stock
| 0.59 | MAIA | MAIA Biotechnology | PairCorr |
| 0.58 | INCR | INC Research Holdings | PairCorr |
| 0.58 | PAHC | Phibro Animal Health Fiscal Year End 4th of September 2024 | PairCorr |
| 0.56 | DCPH | Deciphera Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Vaxart could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vaxart when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vaxart - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vaxart Inc to buy it.
The correlation of Vaxart is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vaxart moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vaxart Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vaxart can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Vaxart Stock Analysis
When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.